Qnity
- Company typePublic
- Founded2025
- HeadquartersSão Paulo, Brazil
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Qnity firmographics
Firmographics- Name
- Qnity
- Legal name
- Qnity Electronics Inc
- Website
- https://qnity.bio
- Company type
- Public
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Qnity industry classification
Industry- Product category
- Molecular Screening Technology
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Quantum Spectroscopy & Chemical/Biological Sensing (HDAGAHAH)
- akta.pro secondary industries
- Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand) (HDAGAEAB), Quantum Sensor Components & Subsystems (Lasers, Vacuum, Photonics, Diamond/NV, MEMS) (HDAGAHAM)
Keywords
Where Qnity is headquartered
LocationHeadquarters
- HQ city
- São Paulo
- HQ country
- Brazil
- HQ region
- Latin America
Offices1 record
Markets served
Qnity business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations
Revenue model
- Semiconductor Materials Supply: Qnity Electronics Inc supplies materials used in semiconductor manufacturing, including CMP polishing pads for advanced chip processing. Revenue is generated through sales of materials to chip manufacturers.
- Molecular Screening Technology: Qnity Bio provides molecular screening services and technology platforms to pharmaceutical companies and researchers for drug discovery applications.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Qnity product offering
Product offeringCore offering
Qnity builds and sells a quantum-electrochemical molecular screening platform centered on a proprietary custom chip with nanogold-silicon electrodes and quantum sensing technology. The device delivers ultra-sensitive drug discovery screening across all molecule sizes, from small organics to complex biologics, offering attomolar-level binding affinity detection and real-time kinetic analysis for pharmaceutical, biotech, and research laboratory customers.
Product overview
Qnity offers a single unified molecular screening platform centered on its proprietary quantum chip. The platform integrates one chip that handles all screening capabilities, delivering real-time molecular data with quantum-level precision for drug discovery applications. The system supports both macro molecule screening and small molecule screening use cases.
Differentiator
Problem solved
Functional benefit
Products and services
- Qnity Molecular Screening Platform A quantum-electrochemical device delivering ultra-sensitive drug discovery and screening across all molecule sizes, from small organics to complex biologics, built on a custom chip with nanogold-silicon electrodes and quantum sensing technology. Targets pharmaceutical companies, biotech firms, and research institutions for drug discovery and therapeutic development applications.
Quantifiable outcome
- Attomolar concentration sensitivity for binding affinity screening
- +1 more outcomes
Companies that use Qnity
Customer profileSegments2 records
Ideal customer profiles1 record
Qnity technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Qnity partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and supporting.
- SK hynixcoreQnity Electronics (DuPont's electronics business) entered a strategic partnership with SK hynix to supply CMP polishing pads for semiconductor manufacturing. The partnership supports SK hynix's next-generation semiconductor processes and expands a long-standing relationship, ahead of Qnity's planned separation from DuPont in November 2025.
- LATAM to Tulsa - TLVcoreSelected Qnity Bio to establish their U.S. headquarters in Tulsa, providing full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding.
- AbiquifisupportingListed as a supporter organization, Brazilian quantum and advanced technology association supporting Qnity's initiatives.
- Apex BrasilsupportingBrazilian trade and investment promotion agency listed as a supporter of Qnity.
- Hello Tomorrow Deep Tech PioneerssupportingGlobal deep tech startup support organization recognizing and supporting Qnity.
- University of OxfordsupportingOxford University and its Oxford University Innovation (OUI) arm listed as supporters, indicating research/academic partnership.
- World Economic ForumsupportingListed as a supporter organization, indicating participation in global innovation and technology initiatives.
Scale indicators4 records
Recent moves9 records
Expansion highlights5 records
Qnity competitors and assessment
Company assessmentBroad incumbents
- Sartorius (Octet): Bio-layer interferometry (BLI) platform for high-throughput, label-free protein interaction and quantitation analysis. The Octet system is a direct substitute technology for the biophysical screening Qnity Bio's chip aims to perform.
- Thermo Fisher Scientific: Largest diversified scientific instrument and life-science tools vendor. Comparable in the analytical instrument category used for pharma/biotech R&D workflows where Qnity Bio's molecular screening platform would be deployed.
- Malvern Panalytical (MicroCal): Provides MicroCal isothermal titration calorimetry (ITC) instruments for measuring binding affinity, stoichiometry, and thermodynamics without labeling. A complementary incumbent technology in the biophysical characterization workflow Qnity Bio targets.
- Cytiva (Biacore): Global leader in surface plasmon resonance (SPR) instruments for label-free binding affinity and kinetics analysis used across pharma drug discovery. Biacore is the dominant incumbent in the molecular interaction analysis category Qnity Bio targets.
- Bruker: Major analytical instrument manufacturer with a broad portfolio spanning mass spectrometry, biophysical characterization, and life-science research tools. Overlaps with Qnity Bio in serving biophysical/binding analytics workflows for pharma and academic customers.
Direct peers
- Nicoya Lifesciences: Develops open-surface SPR and benchtop SPR instruments (Alto and OpenSPR) targeting more accessible, lower-cost kinetic analysis for academic and emerging biotech labs. Comparable as a smaller, technology-focused SPR/biophysics instrument vendor.
- Nanion Technologies: Specialist in high-throughput electrophysiology and binding kinetics platforms for drug discovery. Comparable as a smaller, technology-focused instrument vendor serving pharma/biotech R&D with novel biophysical measurement approaches.
- Carterra: High-throughput SPR platform purpose-built for antibody and biologics discovery, enabling rapid kinetic profiling of large panels. Most direct technology comparable in throughput-oriented binding kinetics for biologics — Qnity Bio's stated macro-molecule focus.
Regional players
- Quantum Design International: Developer of physical property measurement systems including platforms leveraging quantum sensing for materials characterization. Comparable as a vendor of quantum-enabled scientific instrumentation, though primarily focused on materials science rather than life sciences.
Emerging players
- QZabre (Quantum Diamond Technologies): Early-stage developer of quantum diamond (NV-center) sensors for nanoscale magnetic and chemical imaging. Comparable as a quantum-sensing technology company applying similar underlying physics principles to novel measurement applications.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Qnity financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qnity leadership team
Management profileNumber of profiles
Profiles3 records
Qnity funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qnity M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qnity
What does Qnity do?
Qnity builds and sells a quantum-electrochemical molecular screening platform centered on a proprietary custom chip with nanogold-silicon electrodes and quantum sensing technology. The device delivers ultra-sensitive drug discovery screening across all molecule sizes, from small organics to complex biologics, offering attomolar-level binding affinity detection and real-time kinetic analysis for pharmaceutical, biotech, and research laboratory customers.
Is Qnity a public or private company?
Qnity is a public company. It is classified as venture growth investor backed and is currently operating.
When was Qnity founded?
Qnity was founded in 2025. It employs 1 to 10 people.
Where is Qnity based?
Qnity is headquartered in São Paulo, Brazil, in the Latin America region.
How does Qnity make money?
Two revenue lines are on record. Semiconductor Materials Supply is the primary driver. The others are molecular Screening Technology.
Who are Qnity's main competitors?
Broad incumbents on record are Sartorius (Octet), Thermo Fisher Scientific, Malvern Panalytical (MicroCal), Cytiva (Biacore) and Bruker. Direct peers are Nicoya Lifesciences, Nanion Technologies and Carterra. Quantum Design International is listed as a regional player. QZabre (Quantum Diamond Technologies) is listed as an emerging player.
Does Qnity have an API?
No public API is recorded for Qnity.
What industry is Qnity in?
Qnity's product category is Molecular Screening Technology. Its primary akta.pro industry code is HDAGAHAH, Quantum Spectroscopy & Chemical/Biological Sensing, with a secondary code of HDAGAEAB, Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand). Its NAICS code is 334516 and its SIC code is 3826.